+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report by Type (Bivalent, Quadrivalent, Nonavalent), Disease (Cervical Cancer, Anal Cancer), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098137
REQUEST CUSTOMIZATION
Description Jump to:
The Human Papillomavirus Vaccines Market was valued at USD 8.42 billion in 2024, and is projected to reach USD 14.03 billion by 2030, rising at a CAGR of 8.82%., driven by several key factors. The increasing involvement of governments and international health organizations in promoting HPV vaccination is significantly propelling market growth. For instance, in November 2024, the Ministry of Health of the Lao People's Democratic Republic (Lao PDR), in collaboration with UNICEF, the World Health Organization (WHO), and Gavi, the Vaccine Alliance-with support from the Government of Australia-officially launched the 2024 Human Papillomavirus (HPV) immunization campaign. Many countries have introduced HPV vaccines into their national immunization schedules, often with funding support from global organizations such as GAVI, WHO, and PAHO. These collaborations have expanded access to vaccines in low- and middle-income countries, helping overcome cost barriers and logistical challenges.

In addition, school-based vaccination programs have been particularly effective in reaching adolescent populations, which are the primary target for HPV prevention. The Pan American Health Organization’s revolving fund and WHO's prequalification process for new vaccines like Cervavac and Walrinvax have also broadened the landscape of accessible options. As countries increasingly aim to meet the WHO’s goal of eliminating cervical cancer, HPV vaccination is becoming a central pillar in their national strategies, boosting both public and private sector demand and creating significant market opportunities.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

The increasing global prevalence of HPV-related cancers, particularly cervical cancer, is one of the strongest growth drivers of the HPV vaccines market. According to the World Health Organization (WHO), in 2022, cervical cancer was responsible for over 342,000 deaths worldwide, making it the fourth most common cancer among women. Approximately 95% of cervical cancer cases are linked to persistent infection with high-risk HPV types, primarily types 16 and 18. Similarly, the incidence of other HPV-associated cancers-such as oropharyngeal, anal, penile, vaginal, and vulvar cancers-is on the rise, especially in high-income countries. For example, HPV is now responsible for over 70% of oropharyngeal cancers in the United States, a trend that has been steadily increasing over the past decade. This growing disease burden has elevated the role of HPV vaccination in public health agendas. With improved diagnostics and surveillance, and as HPV-related cancer data becomes more robust, the urgency to implement broad vaccination strategies, particularly for adolescents, is accelerating global market demand.

Human Papillomavirus Vaccines Market Report Highlights

  • In 2024, the quadrivalent segment held the largest market share of 75.67%, attributed to its comprehensive protection against four major HPV types-6, 11, 16, and 18. These strains are known to cause nearly 70% of cervical cancer cases and about 90% of genital warts, making the quadrivalent vaccine a key component in HPV immunization strategies worldwide.
  • In 2024, the cervical cancer segment dominated the market, capturing a revenue share of 63.78%, driven by increased awareness and strong preventive measures. Cervical cancer is among the most prevalent HPV-related malignancies, primarily caused by HPV types 16 and 18, which are responsible for approximately 70% of all cases.
  • In 2024, the hospitals and retail pharmacies segment held the largest revenue share of 54.75% and is projected to experience the fastest growth during the forecast period. This trend is primarily driven by the growing accessibility, convenience, and reliability that these healthcare facilities offer to patients seeking HPV vaccination.
  • In 2024, North America led the global market with a share of 39.83%, fueled by extensive immunization coverage, robust public health campaigns, and early adoption of HPV vaccines across both public and private healthcare systems, ensuring broad population protection.
  • The global HPV vaccines market is led by several major companies, including Merck & Co., Inc., GlaxoSmithKline plc (GSK), Serum Institute of India Pvt. Ltd., among others. All key companies are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Disease
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Disease outlook
2.2.3. Distribution channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Human Papillomavirus (HPV) Vaccines Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Rising prevalence of HPV-related cancers
3.4.2. Government and NGO immunization programs
3.4.3. Growing Awareness and education initiatives
3.4.4. Increase in healthcare expenditure
3.4.5. Advancements in vaccine technology
3.5. Market Restraint Analysis
3.5.1. High vaccine costs
3.5.2. Limited Awareness in Underserved Regions
3.5.3. Porter’s Five Forces Analysis
3.5.4. PESTEL Analysis
Chapter 4. Human Papillomavirus (HPV) Vaccines Market: Type Estimates & Trend Analysis
4.1. Human Papillomavirus (HPV) Vaccines Market: Type Movement Analysis
4.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Type
4.3. Bivalent
4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4. Quadrivalent
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Nonavalent
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Human Papillomavirus (HPV) Vaccines Market: Disease Estimates & Trend Analysis
5.1. Human Papillomavirus (HPV) Vaccines Market: Disease Movement Analysis
5.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Disease
5.3. Cervical Cancer
5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Vaginal and Vulvar Cancers
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Anal Cancer
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Oropharyngeal (Head and Neck) Cancers
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Genital Warts
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Human Papillomavirus (HPV) Vaccines Market: Distribution Channel Estimates & Trend Analysis
6.1. Human Papillomavirus (HPV) Vaccines Market: Distribution Movement Analysis
6.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Distribution Channel
6.3. Hospitals and Retail Pharmacies
6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Government Suppliers
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Others
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Human Papillomavirus (HPV) Vaccines Market: Regional Estimates & Trend Analysis
7.1. Human Papillomavirus (HPV) Vaccines Market Share By Region, 2024 & 2030
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Regional Market Dashboard
7.4. Global Regional Market Snapshot
7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.6. North America
7.6.1. North America Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.6.2. U.S.
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. U.S. Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.6.3. Canada
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Canada Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.6.4. Mexico
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. Mexico Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7. Europe
7.7.1. Europe Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.2. UK
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. UK Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.3. Germany
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Germany Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.4. France
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Framework
7.7.4.4. France Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.5. Italy
7.7.5.1. Key Country Dynamics
7.7.5.2. Competitive Scenario
7.7.5.3. Regulatory Framework
7.7.5.4. Italy Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.6. Spain
7.7.6.1. Key Country Dynamics
7.7.6.2. Competitive Scenario
7.7.6.3. Regulatory Framework
7.7.6.4. Spain Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.7. Denmark
7.7.7.1. Key Country Dynamics
7.7.7.2. Competitive Scenario
7.7.7.3. Regulatory Framework
7.7.7.4. Denmark Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.8. Sweden
7.7.8.1. Key Country Dynamics
7.7.8.2. Competitive Scenario
7.7.8.3. Regulatory Framework
7.7.8.4. Sweden Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.7.9. Norway
7.7.9.1. Key Country Dynamics
7.7.9.2. Competitive Scenario
7.7.9.3. Regulatory Framework
7.7.9.4. Norway Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.8. Asia Pacific
7.8.1. Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.8.2. Japan
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Japan Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.8.3. China
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. China Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.8.4. India
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. India Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.8.5. Australia
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Australia Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.8.6. Thailand
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Framework
7.8.6.4. Thailand Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.8.7. South Korea
7.8.7.1. Key Country Dynamics
7.8.7.2. Competitive Scenario
7.8.7.3. Regulatory Framework
7.8.7.4. South Korea Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.9. Latin America
7.9.1. Latin America Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.9.2. Brazil
7.9.2.1. Key Country Dynamics
7.9.2.2. Competitive Scenario
7.9.2.3. Regulatory Framework
7.9.2.4. Brazil Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.9.3. Argentina
7.9.3.1. Key Country Dynamics
7.9.3.2. Competitive Scenario
7.9.3.3. Regulatory Framework
7.9.3.4. Argentina Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.10. MEA
7.10.1. MEA Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.10.2. South Africa
7.10.2.1. Key Country Dynamics
7.10.2.2. Competitive Scenario
7.10.2.3. Regulatory Framework
7.10.2.4. South Africa Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.10.3. Saudi Arabia
7.10.3.1. Key Country Dynamics
7.10.3.2. Competitive Scenario
7.10.3.3. Regulatory Framework
7.10.3.4. Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.10.4. UAE
7.10.4.1. Key Country Dynamics
7.10.4.2. Competitive Scenario
7.10.4.3. Regulatory Framework
7.10.4.4. UAE Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
7.10.5. Kuwait
7.10.5.1. Key Country Dynamics
7.10.5.2. Competitive Scenario
7.10.5.3. Regulatory Framework
7.10.5.4. Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company Categorization
8.3. Strategy Mapping
8.4. Company Market Share Analysis, 2024
8.5. Company Profiles
8.5.1. Merck & Co., Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. GlaxoSmithKline plc (GSK)
8.5.2.1. Overview
8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Serum Institute of India Pvt. Ltd.
8.5.3.1. Overview
8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Sanofi Pasteur SA
8.5.4.1. Overview
8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Pfizer Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Inovio Pharmaceuticals Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Walvax Biotechnology Co., Ltd.
8.5.7.1. Overview
8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Bharat Biotech International Ltd.
8.5.8.1. Overview
8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Johnson & Johnson Services, Inc.
8.5.9.1. Overview
8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Moderna, Inc.
8.5.10.1. Overview
8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Gilead Sciences, Inc.
8.5.11.1. Overview
8.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
List of Table
Table 1 List of abbreviations
Table 2 Global Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 3 Global Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 4 Global Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 5 Global Human Papillomavirus (HPV) Vaccines Market, by Region, 2018-2030 (USD Million)
Table 6 North America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018-2030 (USD Million)
Table 7 North America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 8 North America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 9 North America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 10 U.S. Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 11 U.S. Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 12 U.S. Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 13 Canada Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 14 Canada Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 15 Canada Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 16 Mexico Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 17 Mexico Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 18 Mexico Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 19 Europe Human Papillomavirus (HPV) Vaccines Market, by Country, 2018-2030 (USD Million)
Table 20 Europe Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 21 Europe America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 22 Europe America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 23 UK Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 24 UK Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 25 UK Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 26 Germany Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 27 Germany Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 28 Germany Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 29 France Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 30 France Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 31 France Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 32 Italy Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 33 Italy Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 34 Italy Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 35 Spain Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 36 Spain Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 37 Spain Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 38 Denmark Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 39 Denmark Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 40 Denmark Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 41 Sweden Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 42 Sweden Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 43 Sweden Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 44 Norway Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 45 Norway Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 46 Norway Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 47 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Country, 2018-2030 (USD Million)
Table 48 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 49 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 50 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 51 Japan Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 52 Japan Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 53 Japan Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 54 China Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 55 China Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 56 China Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 57 India Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 58 India Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 59 India Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 60 Australia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 61 Australia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 62 Australia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 63 Thailand Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 64 Thailand Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 65 Thailand Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 66 South Korea Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 67 South Korea Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 68 South Korea Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 69 Latin America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018-2030 (USD Million)
Table 70 Latin America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 71 Latin America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 72 Latin America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 73 Brazil Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 74 Brazil Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 75 Brazil Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 76 Argentina Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 77 Argentina Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 78 Argentina Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 79 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Country, 2018-2030 (USD Million)
Table 80 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by type, 2018-2030 (USD Million)
Table 81 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 82 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 83 South Africa Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 84 South Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 85 South Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 86 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 87 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 88 audi Arabia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 89 UAE Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 90 UAE Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 91 UAE Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
Table 92 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Type, 2018-2030 (USD Million)
Table 93 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018-2030 (USD Million)
Table 94 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 Human Papillomavirus (HPV) Vaccines Market segmentation
Figure 8 Market snapshot, 2024
Figure 9 Market trends & outlook
Figure 10 Market driver relevance analysis (current & future impact)
Figure 11 Market restraint relevance analysis (current & future impact)
Figure 12 SWOT analysis, by factor (political & legal, economic, and technological)
Figure 13 Porter’s five forces analysis
Figure 14 Human papillomavirus (HPV) vaccines market: Type movement analysis
Figure 15 Human papillomavirus (HPV) vaccines market: Type outlook and key takeaways
Figure 16 Bivalent market estimates and forecast, 2018-2030
Figure 17 Quadrivalent market estimates and forecast, 2018-2030
Figure 18 Nonavalent market estimates and forecast, 2018-2030
Figure 19 Human papillomavirus (HPV) vaccines market: Disease movement analysis
Figure 20 Human papillomavirus (HPV) vaccines market: Disease outlook and key takeaways
Figure 21 Cervical Cancer market estimates and forecast, 2018-2030
Figure 22 Vaginal and Vulvar Cancers market estimates and forecast, 2018-2030
Figure 23 Anal Cancer market estimates and forecast, 2018-2030
Figure 24 Oropharyngeal (Head and Neck) Cancers market estimates and forecast, 2018-2030
Figure 25 Genital Warts market estimates and forecast, 2018-2030
Figure 26 Human papillomavirus (HPV) vaccines market: Distribution channel movement analysis
Figure 27 Human papillomavirus (HPV) vaccines market: Distribution channel outlook and key takeaways
Figure 28 Hospitals and Retail Pharmacies market estimates and forecast, 2018-2030
Figure 29 Government Suppliers market estimates and forecast, 2018-2030
Figure 30 Others market estimates and forecast, 2018-2030
Figure 31 Regional outlook, 2024 & 2030
Figure 32 Global Human Papillomavirus (HPV) Vaccines Market: Region movement analysis
Figure 33 North America Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 34 U.S. Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 35 Canada Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 36 Mexico Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 37 Europe Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 38 Germany Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 39 UK Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 40 France Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 41 Italy Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 42 Spain Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 43 Denmark Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 44 Sweden Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 45 Norway Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 46 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 47 Japan Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 48 China Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 49 India Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 50 Australia Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 51 South Korea Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 52 Thailand Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 53 Latin America Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 54 Brazil Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 55 Argentina Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 56 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 57 South Africa Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 58 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 59 UAE Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)
Figure 60 Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018-2030 (USD Million)

Companies Mentioned

The major companies featured in this Human Papillomavirus Vaccines market report include:
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Serum Institute of India Pvt. Ltd.
  • Sanofi Pasteur SA
  • Pfizer Inc.
  • Inovio Pharmaceuticals Inc.
  • Walvax Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Johnson & Johnson Services, Inc.
  • Moderna, Inc.
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.42 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.03 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Human Papillomavirus Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Human Papillomavirus Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 77 Pages
  • Global
From
Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Human Papillomavirus Vaccine Market - Global Forecast 2025-2032 - Product Image

Human Papillomavirus Vaccine Market - Global Forecast 2025-2032

  • Report
  • 189 Pages
  • Global
From
Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 130 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034) - Product Image

Human Papillomavirus (HPV) Vaccine Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.